COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,358 Articles (22,803 medRxiv, 8,555 bioRxiv)

Most recent first Previous |  Page 885: Articles 8841-8850  | Next

Omicron variant of SARS-COV-2 gains new mutations in New Zealand and Hong Kong
Yang, X.-J.
10.1101/2022.03.15.484404 — Posted: 2022-03-15
Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.
Wing, P. A., Prange-Barczynska, M., Cross, A., Crotta, S., Orbegozo Rubio, C., Cheng, X., Harris, J. M., Zhuang, X., Johnson, R. L., Ryan, K. A., Hall, Y., Carroll, M. W., Issa, F., Balfe, P., Wack, A., Bishop, T., Salguero, F. J., McKeating, J. A.
10.1101/2022.03.15.484379 — Posted: 2022-03-15
Vascular dysregulation following SARS-CoV-2 infection involves integrin signaling through a VE-Cadherin mediated pathway
Nader, D., Kerrigan, S.
10.1101/2022.03.15.484274 — Posted: 2022-03-15
Mid-term subclinical myocardial injury detection in patients recovered from COVID-19 according pulmonary lesion severity.
CHAMTOURI, I., Kaddoussi, R., Abroug, H., Abdelali, M., Fahem, N., Lassoued, T., Hafsa, M., Ben Abdallah, A., Achour, A., Chikh'Hmed, S., Migaou, A., Jomaa, W., Sriha, A., ben hamda, k., maatouk, f.
10.1101/2022.03.14.22272130 — Posted: 2022-03-15
Prevalence, determinants, and impact on general health and working capacity of post-acute sequelae of COVID-19 six to 12 months after infection: a population-based retrospective cohort study from southern Germany
Peter, R. S., Nieters, A., Kraeusslich, H.-G., Brockmann, S. O., Goepel, S., Kindle, G., Merle, U., Steinacker, J. M., Rothenbacher, D., Kern, W. V.
10.1101/2022.03.14.22272316 — Posted: 2022-03-15
The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes
Greaney, A. J., Eguia, R. T., Starr, T. N., Khan, K., Franko, N., Logue, J. K., Lord, S. M., Speake, C., Chu, H. Y., Sigal, A., Bloom, J. D.
10.1101/2022.03.12.484088 — Posted: 2022-03-14
Discovery of anti-SARS-CoV-2 molecules using structure-assisted repurposing approach targeting N-protein
Dhaka, P., Singh, A., Choudhary, S., Kumar, P., Sharma, G. K., Tomar, S.
10.1101/2022.03.12.484092 — Posted: 2022-03-14
Dual inhibition of vacuolar ATPase and TMPRSS2 is required for complete blockade of SARS-CoV-2 entry into cells
Icho, S., Rujas, E., Muthuraman, K., Tam, J., Liang, H., Harms, S., Liao, M., Falzarano, D., Julien, J.-P., Melnyk, R.
10.1101/2022.03.11.484006 — Posted: 2022-03-14
Migrants' primary care utilisation before and during the COVID-19 pandemic in England: An interrupted time series
Zhang, C. X., Boukari, Y., Pathak, N., Mathur, R., Katikireddi, S. V., Patel, P., Campos-Matos, I., Lewer, D., Nguyen, V., Hugenholtz, G., Burns, R., Mulick, A. R., Henderson, A., Aldridge, R. W.
10.1101/2022.03.14.22272283 — Posted: 2022-03-14
Acidity of expiratory aerosols controls the infectivity of airborne influenza virus and SARS-CoV-2
Luo, B., Schaub, A., Glas, I., Klein, L. K., David, S. C., Bluvshtein, N., Violaki, K., Motos, G., Pohl, M., Hugentobler, W., Nenes, A., Krieger, U. K., Stertz, S., Peter, T., Kohn, T.
10.1101/2022.03.14.22272134 — Posted: 2022-03-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).